New Therapeutic Approved by FDA to Treat Breast Cancer

Earlier this week, the U.S. Food and Drug Administration approved the molecularly targeted therapeutic ribociclib (Kisqali) for use in combination with any aromatase inhibitor for initial treatment of postmenopausal women with a hormone receptor (HR)–positive, HER2-negative, advanced breast cancer.

Read More

Q&A With Levi Garraway, MD, PhD, on Hot Topics at the International Conference on Molecular Targets and Cancer Therapeutics

Levi Garraway, MD, PhD, co-chair of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston Nov. 5-9, provides insights into the meeting.

Read More